The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Methods Of Cancer Treatment With Antagonists Against Pd-1 And Pd-L1 In Combination With Radiation Therapy - EP3157629

The patent EP3157629 was granted to Medimmune on Oct 5, 2022. The application was originally filed on Jun 17, 2015 under application number EP15733375A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3157629

MEDIMMUNE
Application Number
EP15733375A
Filing Date
Jun 17, 2015
Status
Opposition Rejected
Mar 21, 2025
Publication Date
Oct 5, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TESAROJul 4, 2023DRURYADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2010028330
EXAMINATIONWO2013079174
INTERNATIONAL-SEARCH-REPORTWO2012177624
INTERNATIONAL-SEARCH-REPORTWO2013190555
OPPOSITIONCN102935228
OPPOSITIONWO2012177624
OPPOSITIONWO2013079174
OPPOSITIONWO2014107873
OTHERWO2013079174

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents